ATTBF OTC
Abattis Bioceuticals Corp.
1W: -96.7%
1M: -96.7%
3M: -96.7%
YTD: -96.7%
1Y: -96.7%
3Y: -90.0%
5Y: -100.0%
$0.00
+0.00 (+0.00%)
Overview
Chart
Smart Money
Financials
Income Statement
Cash Flow
Balance Sheet
Earnings
Analysis
Technicals
Weather
Peers
ESG
Institutions
Dark Pool
Short Interest
Income Trends
Revenue
$357K
+4163.2% ▲
5Y CAGR: +115.3%
Gross Profit
$241K
+3626.0% ▲
5Y CAGR: +99.1%
Operating Income
-$4M
+77.2% ▲
Net Income
-$3M
+96.1% ▲
EPS (Diluted)
$-0.01
+97.3% ▲
EBITDA
-$3M
+77.8% ▲
Profit Margins
Year-over-Year Growth
View Full Income Statement
| Line Item | FY2015 | FY2016 | FY2017 | FY2018 | FY2019 |
|---|---|---|---|---|---|
| Revenue | $92K | $0 | $0 | $8K | $357K |
| YoY Growth | +1090.9% | -100.0% | +0.0% | +0.0% | +4163.2% |
| Cost of Revenue | $29K | $0 | $0 | $2K | $116K |
| Gross Profit | $63K | $0 | $0 | $6K | $241K |
| Gross Margin | 68.1% | — | — | 77.4% | 67.6% |
| R&D Expenses | $83K | $40K | $25K | $29K | $0 |
| SG&A Expenses | $3M | $2M | $6M | $16M | $4M |
| Operating Expenses | $3M | $2M | $6M | $16M | $4M |
| Operating Income | -$3M | -$2M | -$6M | -$17M | -$4M |
| Operating Margin | -3347.6% | — | — | -207542.2% | -1108.7% |
| Interest Expense | $19K | $30K | $3K | $4M | $49K |
| Income Before Tax | -$6M | -$2M | -$8M | -$78M | -$3M |
| Tax Expense | -$419K | -$43K | -$286K | $3M | $0 |
| Net Income | -$4M | -$2M | -$8M | -$78M | -$3M |
| Net Margin | -4864.6% | — | — | -931940.1% | -852.4% |
| EPS (Diluted) | $-0.07 | $-0.02 | $-0.05 | $-0.24 | $-0.01 |
| EBITDA | -$3M | -$2M | -$5M | -$17M | -$3M |
| Shares Outstanding | 69M | 95M | 149M | 323M | 470M |